ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Protalix BioTherapeutics, Chiesi Complete Enrollment for Trial of Pegunigalsidase Alfa
September 25, 2019Protalix BioTherapeutics and its development and commercialization partner, Chiesi Farmaceutici announced the completion of enrollment in their Phase III BALANCE clinical study of pegunigalsidase alfa ... -
Protalix BioTherapeutics Appoints President, CEO
May 29, 2019Bashan brings more than 20 years of experience in the pharmaceutical industry. -
Protalix BioTherapeutics Treatment for Ulcerative Colitis Shows Positive Data
March 14, 2018Protalix Biotherapeutics, Inc. believes it’s on the right track in developing an oral medicine for ulcerative colitis that could potentially replace current TNF-inhibitor therapies that are administered via injection or infusion. -
Protalix Wins FDA Approval as Multi-Product Facility
June 05, 2017Protalix BioTherapeutics received approval from the FDA for a Supplemental New Drug Application (sNDA) allowing the company to convert its manufacturing facility in Carmiel, Israel, from a single dedicated product facility to a multi-product facility.
Pharma Sources Insight January 2025
